Europe’s medicines watchdog said on Tuesday the benefits of AstraZeneca's Covid-19 vaccine continue to outweigh the risks after several countries halted its use due to concerns about blood clots. EMA Executive Director Emer Cooke said there was no indication that the blood clot incidents, which she called “very rare” had been caused by the vaccine, but that experts were assessing that possibility. Meanwhile, according to news agency AFP’s tally, Europe’s Covid-19 toll surpassed the grim milestone of over 900,000 deaths. Trust in the safety of the vaccines was paramount and the agency was carrying out a case-by-case evaluation, she said. “The benefits continue to outweigh the risks, but this is a serious concern and it does need serious and detailed scientific evaluation. This is what we are involved in at the moment,” Cooke told a news conference. The results of its findings would be discussed during an EMA review on Thursday after which the results would be made public, Cooke said. Sweden and Latvia on Tuesday suspended use of the vaccine, bringing to more than a dozen the number of EU countries to act since reports first emerged of thromboembolisms affecting people after they got the AstraZeneca shot. A WHO committee of experts was reviewing the cases and was expected to issue a statement by the end of the day, a spokesman said. The EU’s largest members - Germany, France and Italy - suspended use of AstraZeneca's vaccine on Monday pending the outcome of investigations into cases of a rare cerebral thrombosis in people who had received it.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU